Last reviewed · How we verify
live attenuated zoster vaccine
The live attenuated zoster vaccine works by introducing a weakened form of the varicella-zoster virus to stimulate an immune response.
The live attenuated zoster vaccine works by introducing a weakened form of the varicella-zoster virus to stimulate an immune response. Used for Prevention of herpes zoster (shingles).
At a glance
| Generic name | live attenuated zoster vaccine |
|---|---|
| Sponsor | Changchun BCHT Biotechnology Co. |
| Modality | Biologic |
| Therapeutic area | Immunology |
| Phase | Phase 3 |
Mechanism of action
This immune response helps the body recognize and fight the virus, providing protection against shingles. The vaccine is made from a live but weakened virus, which is unable to cause disease but still triggers an immune response.
Approved indications
- Prevention of herpes zoster (shingles)
Common side effects
- Pain, redness, or swelling at the injection site
- Fatigue
- Headache
Key clinical trials
- Study to Evaluate the Safety and Immunogenicity of a Lyophilized Herpes Zoster Virus mRNA Vaccine (PHASE1, PHASE2)
- Co-administration Study of an Investigational Live-Attenuated Respiratory Syncytial Virus Vaccine in Infants and Toddlers (PHASE3)
- The Immunogenicity and Safety of Zostavax® and Shingrix® in Rheumatoid Arthritis Patients Using Abatacept (PHASE2)
- A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase IV Clinical Trial to Evaluate the Immunogenicity and Safety of a Live Attenuated Herpes Zoster Vaccine in Adults Aged 40 Years and Older (PHASE4)
- A Phase III Clinical Trial Assessing the Immunogenicity and Safety of Lyophilized Live-Attenuated Varicella Vaccine in Healthy Subjects Aged 13 to 55 Years (PHASE3)
- Safety and Immunogenicity of Live Attenuated Varicella Vaccine in Healthy Population Aged ≥13 Years Old (PHASE3)
- Long-term Immunogenicity of a Live Herpes Zoster Vaccine in Systemic Lupus Erythematosus (SLE) Patients
- Safety and Immunogenicity of Live Attenuated Varicella Vaccine in Healthy Population Aged ≥13 Years Old (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- live attenuated zoster vaccine CI brief — competitive landscape report
- live attenuated zoster vaccine updates RSS · CI watch RSS
- Changchun BCHT Biotechnology Co. portfolio CI